72 related articles for article (PubMed ID: 8970007)
1. Patient characteristics, MRI examination, and dopaminergic drug response in clinical possible Parkinson's disease.
Larsen JP; Odegaard H; Tandberg E; Hødnebø A; Aarsland D
J Geriatr Psychiatry Neurol; 1996 Oct; 9(4):157-63. PubMed ID: 8970007
[TBL] [Abstract][Full Text] [Related]
2. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease.
Walter U; Dressler D; Probst T; Wolters A; Abu-Mugheisib M; Wittstock M; Benecke R
Arch Neurol; 2007 Nov; 64(11):1635-40. PubMed ID: 17998447
[TBL] [Abstract][Full Text] [Related]
3. [MRI in Parkinson's disease and vascular parkinsonism--study on the lesion of substantia nigra].
Aotsuka A; Shinotoh H; Hirayama K; Ikehira H; Fukuda H
Rinsho Shinkeigaku; 1991 Jun; 31(6):619-24. PubMed ID: 1934776
[TBL] [Abstract][Full Text] [Related]
4. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
Yagi S; Yoshikawa E; Futatsubashi M; Yokokura M; Yoshihara Y; Torizuka T; Ouchi Y
J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
[TBL] [Abstract][Full Text] [Related]
5. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
6. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.
Cummings JL; Henchcliffe C; Schaier S; Simuni T; Waxman A; Kemp P
Brain; 2011 Nov; 134(Pt 11):3146-66. PubMed ID: 21810889
[TBL] [Abstract][Full Text] [Related]
7. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
[TBL] [Abstract][Full Text] [Related]
8. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
10. Compulsive behaviors in patients with Parkinson's disease.
Kenangil G; Ozekmekçi S; Sohtaoglu M; Erginöz E
Neurologist; 2010 May; 16(3):192-5. PubMed ID: 20445429
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
12. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
Lucetti C; Del Dotto P; Gambaccini G; Ceravolo R; Logi C; Berti C; Rossi G; Bianchi MC; Tosetti M; Murri L; Bonuccelli U
Mov Disord; 2007 Nov; 22(15):2170-5. PubMed ID: 17722082
[TBL] [Abstract][Full Text] [Related]
13. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study.
Piccini P; Morrish PK; Turjanski N; Sawle GV; Burn DJ; Weeks RA; Mark MH; Maraganore DM; Lees AJ; Brooks DJ
Ann Neurol; 1997 Feb; 41(2):222-9. PubMed ID: 9029071
[TBL] [Abstract][Full Text] [Related]
15. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
Roth J; Růzicka E; Mecír P
Cas Lek Cesk; 1994 Nov; 133(21):665-7. PubMed ID: 7805088
[TBL] [Abstract][Full Text] [Related]
16. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study.
Ekman U; Eriksson J; Forsgren L; Mo SJ; Riklund K; Nyberg L
Lancet Neurol; 2012 Aug; 11(8):679-87. PubMed ID: 22742929
[TBL] [Abstract][Full Text] [Related]
17. [Comparison study of positron emission tomography, X-ray CT and MRI in parkinsonism with dementia].
Okada J; Peppard R; Calne DB
Nihon Igaku Hoshasen Gakkai Zasshi; 1989 May; 49(5):643-56. PubMed ID: 2798056
[TBL] [Abstract][Full Text] [Related]
18. Multimodal imaging evaluation of excessive daytime sleepiness in Parkinson's disease.
Chondrogiorgi M; Tzarouchi LC; Zikou AK; Astrakas LG; Kosta P; Argyropoulou MI; Konitsiotis S
Int J Neurosci; 2016; 126(5):422-8. PubMed ID: 26000811
[TBL] [Abstract][Full Text] [Related]
19. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
Ozekmekçi S; Apaydin H; Kiliç E
Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
